<DOC>
	<DOCNO>NCT01557140</DOCNO>
	<brief_summary>Chronic Chagas cardiomyopathy cause substantial morbidity mortality Latin America . Whether RAS inhibitor beta-blockers safe beneficial challenge lack formal trial . Hence , objective study determine safety efficacy renin-angiotensin system ( RAS ) inhibitor beta-blockers chronic Chagas cardiomyopathy . This way , investigator conduct double-blind , placebo-controlled , randomized trial 42 patient Trypanosoma cruzi infection cardiomyopathy . All patient receive enalapril ( up-titrated 20 mg BID ) spironolactone ( 25 mg QD ) . Subsequently , patient randomly assign receive placebo ( n = 20 ) carvedilol up-titrated 25 mg BID ( n = 19 ) . The primary end point change leave ventricular ejection fraction ( LVEF ) RAS inhibition addition carvedilol . The secondary end point change echocardiographic parameter , Framingham score , quality life ( 36-item Short-Form Health Survey ) , New York Heart Association class , radiographic index , brain natriuretic peptide level , chemokines well safety end point .</brief_summary>
	<brief_title>A Randomized Trial Carvedilol Chronic Chagas Cardiomyopathy</brief_title>
	<detailed_description>Chronic Chagas cardiomyopathy ( CCC ) important cause heart failure ( HF ) sudden death Latin America.1 According recent estimate , 13 million people worldwide infect Trypanosoma cruzi , 3.0 3.3 million symptomatic.2 The incidence rate 200000 case per year . Among infected , 30 % clinical feature CCC 15 % ultimately develop overt leave ventricular ( LV ) insufficiencyâ€”the main prognostic determinant disease . In Chagas cardiomyopathy , hemodynamic neurohormonal response differ cardiomyopathy . This common pathophysiology suggest treatment show effective classic HF trial beneficial CCC . However , CCC several specific characteristic , early cardiac denervation , frequent ventricular arrhythmia , several form well grade conduction disturbance , include sinus bradycardia , complete atrioventricular block , right bundle-branch block . Morphologically , hypertrophy , dilatation , severe fibrosis prominent . In 20 % 40 % case , apical ventricular aneurysm present.1 These peculiarity combination lead high incidence sudden death ( 60 % death ) , cardiac insufficiency , ventricular remodeling . The response patient usual drug prescribe HF could different , perception lead suboptimal dose lack initiation medical treatment proven efficacy patient etiologies HF . The underlie problem therapy effective patient HF cause non-chagasic cardiomyopathy , renin-angiotensin system inhibitor ( RASis ) h-blockers , yet formally test CCC . There clinical trial randomize study subject . Consequently , investigator evaluate effect optimize treatment enalapril spironolactone undertook randomize trial add h-blocker treatment patient CCC .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Chagas Cardiomyopathy</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<criteria>Criteria inclusion positivity T cruzi confirm 2 serological test ( indirect immunofluorescence , ELISA , and/or indirect hemagglutination ) cardiomyopathy . Cardiomyopathy present least 3 follow criterion fulfil : LV enddiastolic diameter ( LVDD ) N55 mm LVDD/body surface area &gt; 2.7cm/m2 LV ejection fraction ( LVEF ) &lt; 55 % QRS interval &gt; 120 m echocardiographic evidence diffuse segmental systolic wall motion abnormality . Exclusion criterion pregnant Using hblocker Having additional comorbidities ( eg , hypertension , diabetes mellitus , thyroid dysfunction , chronic obstructive pulmonary disease , asthma , renal hepatic failure ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Chagas cardiomyopathy ,</keyword>
	<keyword>Renin-angiotensin system ,</keyword>
	<keyword>Beta-blockers ,</keyword>
	<keyword>Enalapril ,</keyword>
	<keyword>Carvedilol ,</keyword>
	<keyword>Renin-angiotensin system inhibitor ,</keyword>
	<keyword>Brain natriuretic peptide level ,</keyword>
	<keyword>Left ventricular ejection fraction ,</keyword>
	<keyword>Chemokines</keyword>
</DOC>